Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences

被引:24
作者
Uch, R
Gérolami, R
Faivre, J
Hardwigsen, J
Mathieu, S
Mannoni, P
Bagnis, C
机构
[1] Estab Francais Sang Alpes Mediterranee, Dept Therapie Cellulaire & Gen, F-13392 Marseille 5, France
[2] Fac Med Timone, INSERM, U559, Marseille, France
[3] Fac Necker, INSERM, U370, Paris, France
[4] Hop Conception, Serv Transplantat Hepat, Marseille, France
关键词
lentiviral vector; alpha-fetoprotein; HSV-TkEGFP; hepatocellular carcinoma;
D O I
10.1038/sj.cgt.7700621
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Suicide gene therapy combining herpes simplex virus thymidine kinase gene transfer and ganciclovir administration can be envisioned as a powerful therapeutical approach in the treatment of hepatocellular carcinoma; however, safety issues regarding transgene expression in parenchyma cells have to be addressed. In this study, we constructed LATKW, a lentiviral vector expressing the HSV-TkEGFP gene placed under the control of the promoter elements that control the expression of the rat alpha-fetoprotein, and assayed its specific expression in vitro in hepatocarcinoma and nonhepatocarcinoma human cell lines, and in epidermal growth factor stimulated human primary hepatocytes. Using LATKW, a strong expression of the transgene was found in transduced hepatocarcinoma cells compared to a very low expression in nonhepatocarcinoma human cell lines, as assessed by Northern blot, RT-PCR, FACS analysis and ganciclovir-mediated toxicity assay, and no expression was found in lentivirally transduced normal human hepatocytes. Altogether, these results demonstrate the possibility to use a lentivirally transduced expression unit containing the rat alpha-fetoprotein promoter to restrict the HSV-TK-mediated induced GCV sensitivity to human hepatocarcinoma cells.
引用
收藏
页码:689 / 695
页数:7
相关论文
共 28 条
[1]  
Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO
[2]  
2-Q
[3]   Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences [J].
Arbuthnot, P ;
Bralet, MP ;
Thomassin, H ;
Danan, JL ;
Brechot, C ;
Ferry, N .
HEPATOLOGY, 1995, 22 (06) :1788-1796
[4]   In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector [J].
Arbuthnot, PB ;
Bralet, MP ;
LeJossic, C ;
Dedieu, JF ;
Perricaudet, M ;
Brechot, C ;
Ferry, N .
HUMAN GENE THERAPY, 1996, 7 (13) :1503-1514
[5]   Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma:: The woodchuck animal model [J].
Bilbao, R ;
Gérolami, R ;
Bralet, MP ;
Qian, C ;
Tran, PL ;
Tennant, B ;
Prieto, J ;
Bréchot, C .
CANCER GENE THERAPY, 2000, 7 (05) :657-662
[6]   LIVER RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC-PATIENTS [J].
BISMUTH, H ;
CHICHE, L ;
ADAM, R ;
CASTAING, D ;
DIAMOND, T ;
DENNISON, A .
ANNALS OF SURGERY, 1993, 218 (02) :145-151
[7]   Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach [J].
Brand, K ;
Loser, P ;
Arnold, W ;
Bartels, T ;
Strauss, M .
GENE THERAPY, 1998, 5 (10) :1363-1371
[8]  
Brand K, 1997, CANCER GENE THER, V4, P9
[9]   Impact of HBV HCV and GBV-C/HGV on hepatocellular carcinomas in Europe:: results of a European concerted action [J].
Bréchot, C ;
Jaffredo, F ;
Lagorce, D ;
Gerken, G ;
zum Büschenfelde, KM ;
Papakonstontinou, A ;
Hadziyannis, S ;
Romeo, R ;
Colombo, M ;
Rodes, J ;
Bruix, J ;
Williams, R ;
Naoumov, N .
JOURNAL OF HEPATOLOGY, 1998, 29 (02) :173-183
[10]   Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma [J].
Colombo, M .
JOURNAL OF HEPATOLOGY, 1999, 31 :25-30